Skip to content

Virtual Versus Dye-based Chromoendoscopy in Inflammatory Bowel Disease Surveillance Colonoscopy

Virtual Versus Dye-based Chromoendoscopy in Inflammatory Bowel Disease Surveillance Colonoscopy

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07089771
Enrollment
480
Registered
2025-07-28
Start date
2026-05-01
Completion date
2032-12-31
Last updated
2026-03-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammatory Bowel Disease (IBD), Ulcerative Colitis (Disorder), Crohns Disease, Colorectal Neoplasms

Keywords

virtual chromoendoscopy, dye-based chromoendoscopy, dysplasia detection, IBD surveillance colonoscopy

Brief summary

People with inflammatory bowel disease (IBD), such as ulcerative colitis or Crohn's disease affecting the colon, have a higher risk of developing colon cancer over time. To catch early signs of cancer, regular colonoscopies are recommended. In this study, the investigators are comparing two advanced methods of examining the colon during these surveillance colonoscopies. One method uses a special dye sprayed inside the colon to highlight abnormal areas (called dye-based chromoendoscopy). The other method uses new technology built into the camera to enhance the view without needing any dye (called virtual chromoendoscopy). Both methods use modern, high-definition equipment. The purpose of this study is to find out if the newer, dye-free method is as good as the traditional dye method at detecting pre-cancerous changes (called dysplasia) in people with IBD. Adults with IBD who are due for a routine surveillance colonoscopy may be invited to take part. Participants will be randomly assigned to one of the two methods. No additional procedures are involved, and only the way the colon is viewed differs. The investigators will also look at how long the procedures take, how many biopsies are needed, any complications, and how patients experience the exam. Participants will be followed over time using national health records to check for long-term outcomes. This research will help doctors better understand which method is most effective and comfortable for patients, and may guide future recommendations for cancer screening in people with IBD.

Detailed description

This is a multicenter, prospective, randomized, non-inferiority clinical trial designed to compare the diagnostic performance of two high-definition endoscopic imaging techniques used during surveillance colonoscopy in patients with longstanding inflammatory bowel disease (IBD) who are at increased risk for colorectal cancer. Participants will be randomly assigned to undergo colonoscopy using either a virtual (dye-free) chromoendoscopy method or a conventional dye-based chromoendoscopy technique. The primary objective is to evaluate whether virtual chromoendoscopy is non-inferior to dye- based chromoendoscopy in detecting dysplasia, a precancerous condition in the colon. Secondary outcomes include the number and type of lesions detected, predictive accuracy of targeted biopsies, examination times, patient-reported experience, complication rates, and biopsy frequency. Eligible participants are adults with a history of extensive colonic IBD of at least eight years, or additional high-risk factors such as primary sclerosing cholangitis or family history of colorectal cancer. Patients with previous colorectal cancer, prior colectomy, known untreated dysplasia, or contraindications to dye application will be excluded. All procedures will be performed using high-definition equipment and standardized bowel preparation protocols. The study includes long-term follow-up through national health registries to evaluate cancer outcomes and subsequent procedures at one and three years post-colonoscopy. The trial will be conducted across several academic and regional centers in Sweden, with an anticipated enrollment of approximately 480 patients to account for potential attrition. This study seeks to inform future guidelines by determining whether a less resource-intensive and potentially more patient-friendly method can provide equivalent surveillance efficacy in this high-risk population.

Interventions

High-Definition Virtual Chromoendoscopy (HD-VCE): Surveillance colonoscopy using high-definition virtual chromoendoscopy enhances mucosal visualization through advanced imaging filters integrated into the colonoscope. This dye-free technique improves detection of dysplasia by increasing contrast and highlighting subtle mucosal patterns during withdrawal. HD-VCE reduces procedure time and eliminates risks related to dye application, offering a practical alternative to dye-based methods. Its efficacy in IBD surveillance requires further validation.

PROCEDUREDye-Based Chromoendoscopy

High-Definition Dye-Based Chromoendoscopy (HD-DCE): Surveillance colonoscopy using high-definition dye-based chromoendoscopy involves segmental application of indigo carmine dye via a spray catheter. The dye enhances mucosal surface patterns, aiding dysplasia detection. HD-DCE is currently considered a gold standard in IBD surveillance due to superior dysplasia detection rates.

Sponsors

Region Stockholm
Lead SponsorOTHER_GOV
Uppsala University Hospital
CollaboratorOTHER
Sahlgrenska University Hospital
CollaboratorOTHER
Falu Hospital
CollaboratorOTHER
Karolinska University Hospital
CollaboratorOTHER
Örebro University, Sweden
CollaboratorOTHER
Ersta Diakoni
CollaboratorOTHER
Saint Göran Hospital
CollaboratorUNKNOWN
University Hospital, Linkoeping
CollaboratorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Intervention model description

This study uses a parallel assignment model, where participants with inflammatory bowel disease undergoing surveillance colonoscopy are randomly assigned to one of two groups: high-definition virtual chromoendoscopy (HD-VCE) or high-definition dye-based chromoendoscopy (HD-DCE). Each participant receives only one of the two interventions, and outcomes are compared between these independent groups. Randomization is performed prior to the procedure. The parallel design allows direct comparison of dysplasia detection rates between the two techniques without carryover effects, making it appropriate for evaluating the non-inferiority of HD-VCE compared to the current standard HD-DCE.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥ 18 years and one of the criteria beneath: * Extensive ulcerative colitis or indeterminate colitis (IBD-U), or Crohn's colitis involving at least one-third of the colon, with a disease history of at least 8 years * IBD or IBD-U with primary sclerosing cholangitis (PSC) * IBD or IBD-U with a family history of colorectal cancer in a first-degree relative

Exclusion criteria

* History of colorectal cancer or prior colectomy * Contraindications to dye use * Colonoscopies for therapeutic purposes * Pregnancy * Inability to consent

Design outcomes

Primary

MeasureTime frameDescription
Proportion of patients with at least one dysplastic lesion detected during surveillance colonoscopyMeasured at the time of the index colonoscopy procedure (baseline) and confirmed by histopathological analysis post-procedure (up to 60 days)The primary endpoint is the proportion of enrolled patients in each study arm (HD-VCE and HD-DCE) who have at least one histologically confirmed dysplastic lesion (including low-grade dysplasia, high-grade dysplasia, or colorectal cancer) detected during the index surveillance colonoscopy.

Secondary

MeasureTime frameDescription
Number of dysplastic lesions detected per 10 minutes of withdrawal timeMeasured during the index colonoscopy procedure.The rate of dysplastic lesions detected normalized by the colonoscope withdrawal time (number of dysplasia findings per 10 minutes) during the surveillance colonoscopy.
Positive predictive value (PPV) of targeted biopsiesMeasured during the index colonoscopy and confirmed by pathology.The proportion of biopsies taken from suspicious lesions that are confirmed histologically as dysplastic or neoplastic.
Type and characterization of detected lesionsAssessed at the time of index colonoscopy and confirmed by pathology.Classification and histopathological characterization of lesions detected, including cancer, adenomas with low- or high-grade dysplasia, sessile serrated lesions (with or without dysplasia), hyperplastic polyps, inflammatory or post-inflammatory polyps, and non-dysplastic lesions.
Patient experience and satisfactionCollected within 24-48 hours after the colonoscopy procedure.Self-reported patient experience and satisfaction scores collected using the validated survey Patient Experience Colonoscopy Scale (PECS), evaluating comfort and acceptability of each colonoscopy method. Survey responses are rated on a 4-point Likert scale ranging from very poor agreement to very good agreement, with higher values representing better outcomes.

Countries

Sweden

Contacts

CONTACTOlga Bednarska, MD PhD
olga.bednarska@regionstockholm.se0046703980931

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 21, 2026